About Serine protease HTRA2, mitochondrial
Serine protease HTRA2, mitochondrial (HTRA2) is a protein
from Homo sapiens identified by UniProt accession
O43464, 458 residues long.
MolForge cross-references it against 0 known binders and
356 disease associations.
Target properties
| Protein name | Serine protease HTRA2, mitochondrial |
| UniProt accession | O43464 |
| Gene | HTRA2 |
| Organism | Homo sapiens |
| Length | 458 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (356)
Diseases linked to this target (Open Targets).
- 3-methylglutaconic aciduria type 8 · score 0.80
- 3-methylglutaconic aciduria · score 0.50
- Young adult-onset Parkinsonism · score 0.49
- neutropenia · score 0.46
- genetic disorder · score 0.19
- Leigh syndrome · score 0.15
- breast ductal adenocarcinoma · score 0.11
- hepatocellular carcinoma · score 0.10
- rheumatoid arthritis · score 0.09
- Rheumatoid arthritis · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O43464-F1 | alphafold | PREDICTED | 74.45 | — |
Amino-acid sequence (458 residues)
MAAPRAGRGA GWSLRAWRAL GGIRWGRRPR LTPDLRALLT SGTSDPRARV TYGTPSLWAR LSVGVTEPRA CLTSGTPGPR AQLTAVTPDT RTREASENSG TRSRAWLAVA LGAGGAVLLL LWGGGRGPPA VLAAVPSPPP ASPRSQYNFI ADVVEKTAPA VVYIEILDRH PFLGREVPIS NGSGFVVAAD GLIVTNAHVV ADRRRVRVRL LSGDTYEAVV TAVDPVADIA TLRIQTKEPL PTLPLGRSAD VRQGEFVVAM GSPFALQNTI TSGIVSSAQR PARDLGLPQT NVEYIQTDAA IDFGNSGGPL VNLDGEVIGV NTMKVTAGIS FAIPSDRLRE FLHRGEKKNS SSGISGSQRR YIGVMMLTLS PSILAELQLR EPSFPDVQHG VLIHKVILGS PAHRAGLRPG DVILAIGEQM VQNAEDVYEA VRTQSQLAVQ IRRGRETLTL YVTPEVTE
Explore Serine protease HTRA2, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets